血管压缩剂数量与COVID-19患者死亡率之间的关联
Michael Sunnaa1, Mina Kerolos1, Max Ruge2
1Rush University Medical Center, Chicago, IL, United States.
概括
需要血管压缩剂的重症COVID-19患者面临着显著更高的60天死亡率. 风险随着每一个额外的血管压缩剂的增加而大幅增加,突出显示了这些患者的疾病严重程度.
科学领域:
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- COVID-19可能导致严重疾病,需要进入重症监护室 (ICU).
- 血管压缩剂通常用于重症患者治疗低血压.
- 同时服用血管压缩剂的数量对COVID-19患者的结局的影响尚未完全理解.
研究的目的:
- 调查重症COVID-19患者同时使用的血管压缩剂数量与临床结果之间的关联.
- 为了确定60天死亡风险,根据血管压缩剂的要求分层分层.
主要方法:
- 一个单一中心的回顾性队列研究.
- 包括2020年3月至10月期间因COVID-19而入住ICU的成年患者.
- 分析60天死亡率,根据接受的血管压缩剂的数量 (0,1,2,3或4-5).
主要成果:
- 在637名患者中,338人需要血管压缩剂.
- 与没有血管压缩剂相比,患有1种血管压缩剂 (aOR 3.27),2种 (aOR 4.71),3种 (aOR 26.2) 和4-5种 (aOR 106.38) 的患者死亡风险增加.
- 住院死亡率从6.7% (没有血管压缩剂) 到78% (4-5血管压缩剂) 之间.
结论:
- 需要血管压缩剂的重症COVID-19患者的60天死亡率明显更高.
- 血管压缩剂数量的增加与死亡风险的增加密切相关.
- 这突显了COVID-19患者需要血管压缩剂支持的疾病严重程度和管理的复杂性.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
01:17Measurement of Blood Pressure
924
Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
924
01:21Acute Respiratory Failure-II
222
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
222
01:28Factors affecting Blood pressure
3.2K
Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
Physiological Factors:
3.2K
01:29Acute Respiratory Failure-V
137
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
137